

**Summary of Consolidated Financial Results for  
the Second Quarter of the Fiscal Year Ending March 31, 2025  
(Six Months Ended September 30, 2024)**

[Japanese GAAP]

Company name: NIHON TRIM CO., LTD. Listing: Tokyo Stock Exchange  
 Securities code: 6788 URL: <https://www.nihon-trim.co.jp/>  
 Representative: Norio Tahara, President  
 Contact: Kojiro Oda, Senior Managing Executive Officer and General Manager of Administration Division  
 Tel: +81-(0) 6-6456-4600

Scheduled date of filing Semi-annual Report: November 14, 2024  
 Scheduled date of dividend payment: –  
 Supplementary materials for financial results: Yes  
 Holding of financial results meeting: Yes (for institutional investors)

(All amounts are rounded down to the nearest million yen)

**1. Consolidated Financial Results for the Six Months Ended September 30, 2024 (April 1, 2024 - September 30, 2024)**

## (1) Consolidated results of operations

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended Sep. 30, 2024	11,361	8.7	1,856	10.1	1,949	10.5	1,306	9.4
Six months ended Sep. 30, 2023	10,452	15.1	1,686	38.1	1,764	36.3	1,193	40.8

Note: Comprehensive income (million yen) Six months ended Sep. 30, 2024: 1,470 (up 6.1%)

Six months ended Sep. 30, 2023: 1,386 (up 32.5%)

	Net income per share	Diluted net income per share
	Yen	Yen
Six months ended Sep. 30, 2024	170.40	–
Six months ended Sep. 30, 2023	155.76	–

## (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of Sep. 30, 2024	32,633	24,409	70.3	2,992.42
As of Mar. 31, 2024	31,544	23,627	70.7	2,911.21

Reference: Shareholders' equity (million yen) As of Sep. 30, 2024: 22,936 As of Mar. 31, 2024: 22,314

**2. Dividends**

	Dividend per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended Mar. 31, 2024	–	0.00	–	85.00	85.00
Fiscal year ending Mar. 31, 2025	–	0.00	–	–	–
Fiscal year ending Mar. 31, 2025 (forecasts)	–	–	–	95.00	95.00

Note: Revisions to the most recently announced dividend forecast: None

**3. Consolidated Forecast for the Fiscal Year Ending March 31, 2025 (April 1, 2024 - March 31, 2025)**

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	22,800	11.7	3,570	15.9	3,700	14.7	2,470	14.9	322.24

Note: Revisions to the most recently announced consolidated forecast: None

**\* Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly added: – Excluded: –

(2) Application of special accounting methods for presenting semi-annual consolidated financial statements: None

(3) Changes in accounting policies and accounting estimates, and restatements

(i) Changes in accounting policies due to revisions in accounting standards, others: None

(ii) Changes in accounting policies other than (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of outstanding shares (common shares)

(i) Number of shares issued at end of period (including treasury shares)

As of Sep. 30, 2024: 8,656,780 shares

As of Mar. 31, 2024: 8,656,780 shares

(ii) Number of treasury shares at end of period

As of Sep. 30, 2024: 991,856 shares

As of Mar. 31, 2024: 991,758 shares

(iii) Average number of shares outstanding during the period

Six months ended Sep. 30, 2024: 7,664,985 shares

Six months ended Sep. 30, 2023: 7,665,113 shares

Note: The Company has adopted the Employee Stock Ownership Plan (J-ESOP). The company shares held by this trust is included in the number of treasury shares, which are to be deducted from the calculation of the number of treasury shares at end of period and the average number of shares outstanding during the period.

\* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

\* Cautionary statement with respect to forward-looking statements, and other special items

Earnings forecasts regarding future performance in this material are based on assumptions judged to be valid and information currently available to the Company, and the Company does not in any way guarantee the achievement of the forecasts. Actual results may differ significantly from these forecasts for a number of factors. Please refer to “1. Overview of Results of Operations, etc., (3) Explanation of the Future Outlook, including Consolidated Performance Forecasts” on page 4 of the attachments for assumptions for forecasts and notes of caution for usage.

**Contents of Attachments**

1. Overview of Results of Operations, etc.	2
(1) Overview of Results of Operations for the Period under Review	2
(2) Overview of Financial Position for the Period under Review	4
(3) Explanation of the Future Outlook, including Consolidated Performance Forecasts	4
2. Semi-annual Consolidated Financial Statements and Notes	5
(1) Semi-annual Consolidated Balance Sheet	5
(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income	7
Semi-annual Consolidated Statement of Income	7
Semi-annual Consolidated Statement of Comprehensive Income	8
(3) Semi-annual Consolidated Statement of Cash Flows	9
(4) Notes to Semi-annual Consolidated Financial Statements	11
Assumption for Going Concern	11
Significant Changes in Shareholders' Equity	11
Segment and Other Information	11

## 1. Overview of Results of Operations, etc.

### (1) Overview of Results of Operations for the Period under Review

The Nihon Trim Group (“the Group”) is committed to “contributing to the creation of healthy and comfortable lives” under its corporate philosophy. To this end, the Group operates its business under the main theme of health and medical care. The Group’s mission is to contribute to people’s well-being through its businesses including Electrolyzed Hydrogen Water (EHW), electrolyzed water hemodialysis, and regenerative medicine. The Group’s EHW apparatus is a controlled medical device that has been approved for its effects on improvement of gastrointestinal conditions, and its water purification cartridge is equipped with a function to remove PFAS (generic name for organic fluorine compounds) (\*1), whose environmental impact has become a global issue in recent years, thereby contributing to the creation of an environment where people can live with peace of mind. Under the slogan “Society will always need our products, at any point in time,” the Group will contribute to the realization of a sustainable society and achieve sustainable enhancement of its corporate and shareholder value.

(\*1) Water purification capacity was tested using the method specified in voluntary standards of Japan Water Purifier Association (JWPAS B). We have confirmed that the removal rate of PFOS and PFOA, which are particularly harmful among PFAS, is 80% or higher for all types of our water purification cartridges (results of JWPAS B.210 test).

During the first six months of the current fiscal year, the Group’s net sales increased 8.7% year on year to 11,361 million yen, hitting a record high on a semi-annual basis. The Group’s operating profit increased 10.1% to 1,856 million yen, ordinary profit increased 10.5% to 1,949 million yen, and profit attributable to owners of parent increased 9.4% to 1,306 million yen, recording new highs in semi-annual operating profit and ordinary profit. Both sales and profit targets have been achieved ahead of the consolidated forecast announced on May 14, 2024, with net sales, operating profit, ordinary profit, and profit attributable to owners of parent reaching 101.0%, 107.9%, 108.9%, and 103.7% of the semi-annual consolidated forecast, respectively.

Setting a target of 32,000 million yen in consolidated net sales for the fiscal year ending March 31, 2027, we have focused on the following three points to achieve this goal and enhance our corporate value over the medium to long term.

1. Expanding business volume of the direct sales divisions in our main business of EHW apparatus sales.
2. Expanding overseas operations of the OEM and wholesale sales division of the EHW apparatus sales business.
3. Promoting the widespread use of electrolyzed water hemodialysis as the first of its kind in the world and conducting research and development activities with an eye to having the treatment covered by public insurance.

Results by business segment were as follows.

#### Water Healthcare Business

In the EHW apparatus sales business, net sales of EHW apparatus increased 1.3% year on year to 4,871 million yen.

In the DS Division (workplace sales division), seminar numbers have steadily increased amid an increase in the number of workplaces engaging in the maintenance and promotion of the health of their employees. The total introduction of products to workplaces resulting from proposals centered on health and productivity management as well as development into the sports and beauty care fields, which we have been focusing on since last year, have contributed to improving sales efficiency, and we have made steady progress toward the plan for the current fiscal year. Our focus on increasing sales personnel has produced positive results, and we will work diligently to further expand sales. In the HS Division (installation and referral sales division), the number of units sold per sales person increased. The SS Division (in-store event sales division) made steady progress, partly due to an increase in the number of units ordered as a result of increased visitors to exhibitions and other events.

In the MS Division (OEM and wholesale sales division), net sales decreased year on year. Behind this was a significant increase in the number of shipments owing to successful campaign measures taken by existing OEM

partners in the previous fiscal year, although the effects of strengthening sales support have been steadily coming to fruition. In addition, we have focused on acquiring new domestic OEM partners and new agents for overseas transactions, and have worked diligently to start operation of new agents in the second half and beyond.

With regard to sales of water purification cartridges in Japan, which generate a consistent revenue stream once an EHW apparatus is installed, we have made efforts to strengthen customer service, including information distribution and follow-up by telephone, resulting in steady growth with net sales of 2,947 million yen (up 4.5% year on year).

PT. SUPER WAHANA TEHNO, which operates a bottled water business in Indonesia, maintained significant growth with net sales of 1,531 million yen (up 59.0% year on year), a record high on a semi-annual basis. Enduring from the previous fiscal year, brand awareness of Pristine has continued to drastically increase due to the further strengthening of marketing measures through TV commercials, advertisements on social networking services featuring influencers, etc. in the current fiscal year. In order to respond to the strong influx of demand, we are considering specific measures for the construction of a new factory to further grow business performance.

In the field of research and development, we have continuously worked on research aimed at identifying the mechanism for the benefits of EHW as well as looking for new business seeds jointly with RIKEN, Tohoku University, Waseda University, and others, such as “Essential Health Care Science Collaborative Research Program” with Kobe University.

In October this year, as a result of research that we worked on with the University of Tokyo, a paper on the development of new electrocatalysts was printed in the Journal of Materials Chemistry A published by the Royal Society of Chemistry (Impact factor: 10.7 (2023)).

In the future, in addition to the development of new products, we will work on the practical application of this research in high-efficiency hydrogen production technology with an eye toward business development in the energy field.

As a result of the above, the water healthcare business recorded net sales of 9,943 million yen (up 8.5% year on year), with segment profit of 1,641 million yen (up 10.0% year on year).

### **Medical Business**

In the electrolyzed water hemodialysis (\*2) business, following the 69th Annual Meeting of the Japanese Society for Dialysis Therapy in June this year, we have been vigorously engaging in marketing activities through initiatives including exhibiting at subsequent events such as the 35th Annual Meeting of the Japan Society for Blood Purification in Critical Care held in October and the 30th Annual Meeting of Japanese Society for Hemodiafiltration held in November. Awareness of and interest in electrolyzed water hemodialysis has experienced a tangible rise, and is steadily spreading. In addition, we will work toward the development of new machines to expand their use.

(\*2) Electrolyzed water hemodialysis offers a next-generation of new dialysis treatment using electrolyzed RO water with a unique feature of containing dissolved hydrogen, which is produced by our technology, to dilute dialysate. It is unconventional technology that focuses attention on the functions of water as a solvent for the first time in the world. We obtained data that showed that electrolyzed water hemodialysis reduced the dosage of drugs after the treatment and the annual crude death rate (CDR) of patients compared to traditional hemodialysis, which has drawn attention.

In the field of regenerative medicine, StemCell Institute Inc. (listed on TSE Growth Market, Securities Code: 7096, our share: 72.1%) achieved new record highs in semi-annual net sales and profit at each stage. The company published its earnings results for the six months ended September 30, 2024, on November 12 this year, the same date as did the Group. For details, please refer to the StemCell Institute’s Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2025.

As a result of the above, the medical business recorded net sales of 1,418 million yen (up 9.7% year on year) with segment profit of 214 million yen (up 10.5% year on year).

**(2) Overview of Financial Position for the Period under Review**

Total assets increased 1,088 million yen, or 3.5%, from the end of the previous fiscal year to 32,633 million yen at the end of the first half of the current fiscal year on a consolidated basis. The main factors were an increase in cash and deposits of 1,699 million yen, despite a decrease in securities of 502 million yen.

Total liabilities increased 306 million yen, or 3.9%, from the end of the previous fiscal year to 8,224 million yen. The main factors were increases in advances received of 193 million yen, long-term guarantee deposits included in other under non-current liabilities of 66 million yen, and provision for share-based payments of 44 million yen.

Net assets increased 781 million yen, or 3.3%, from the end of the previous fiscal year to 24,409 million yen. The main factors were the recognition of profit attributable to owners of parent of 1,306 million yen and an increase in non-controlling interests of 159 million yen, which were partially offset by a decrease resulting from dividend payments of 688 million yen.

**(3) Explanation of the Future Outlook, including Consolidated Performance Forecasts**

There are no revisions to the full-year consolidated forecast for the fiscal year ending March 31, 2025, which was announced in the “Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2024,” dated May 14, 2024.

**2. Semi-annual Consolidated Financial Statements and Notes****(1) Semi-annual Consolidated Balance Sheet**

	(Thousands of yen)	
	FY3/24 (As of Mar. 31, 2024)	First half of FY3/25 (As of Sep. 30, 2024)
<b>Assets</b>		
<b>Current assets</b>		
Cash and deposits	13,959,093	15,658,644
Notes and accounts receivable-trade	5,758,101	6,259,326
Securities	1,302,898	800,000
Finished goods	604,471	625,315
Raw materials and supplies	1,064,684	1,078,842
Other	255,646	239,355
Allowance for doubtful accounts	(25,056)	(25,911)
<b>Total current assets</b>	<b>22,919,840</b>	<b>24,635,572</b>
<b>Non-current assets</b>		
<b>Property, plant and equipment</b>		
Land	2,579,253	2,582,675
Other, net	1,851,348	1,876,784
<b>Total property, plant and equipment</b>	<b>4,430,601</b>	<b>4,459,460</b>
<b>Intangible assets</b>		
Goodwill	348,910	330,350
Other	243,763	289,900
<b>Total intangible assets</b>	<b>592,674</b>	<b>620,251</b>
<b>Investments and other assets</b>		
Investment securities	1,767,309	1,477,836
Other	1,883,448	1,489,454
Allowance for doubtful accounts	(49,113)	(49,113)
<b>Total investments and other assets</b>	<b>3,601,644</b>	<b>2,918,178</b>
<b>Total non-current assets</b>	<b>8,624,920</b>	<b>7,997,889</b>
<b>Total assets</b>	<b>31,544,761</b>	<b>32,633,462</b>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Accounts payable-trade	550,221	580,777
Income taxes payable	740,198	694,225
Advances received	3,702,438	3,896,418
Provision for bonuses	185,000	197,018
Provision for product warranties	84,000	89,000
Other	1,368,342	1,353,864
<b>Total current liabilities</b>	<b>6,630,202</b>	<b>6,811,304</b>
<b>Non-current liabilities</b>		
Provision for share-based payments	88,800	133,544
Provision for retirement benefits for directors (and other officers)	299,572	269,430
Retirement benefit liability	407,417	420,906
Other	491,421	588,971
<b>Total non-current liabilities</b>	<b>1,287,211</b>	<b>1,412,853</b>
<b>Total liabilities</b>	<b>7,917,414</b>	<b>8,224,157</b>

	(Thousands of yen)	
	FY3/24 (As of Mar. 31, 2024)	First half of FY3/25 (As of Sep. 30, 2024)
Net assets		
Shareholders' equity		
Share capital	992,597	992,597
Capital surplus	1,823,945	1,823,945
Retained earnings	22,838,855	23,456,657
Treasury shares	(3,448,320)	(3,448,670)
Total shareholders' equity	22,207,077	22,824,530
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	64,947	(10,323)
Foreign currency translation adjustment	49,075	127,734
Remeasurements of defined benefit plans	(6,603)	(5,281)
Total accumulated other comprehensive income	107,420	112,128
Non-controlling interests	1,312,848	1,472,645
Total net assets	23,627,347	24,409,304
Total liabilities and net assets	31,544,761	32,633,462



**(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income**  
**Semi-annual Consolidated Statement of Income**

	(Thousands of yen)	
	First six months of FY3/24 (Apr. 1, 2023 - Sep. 30, 2023)	First six months of FY3/25 (Apr. 1, 2024 - Sep. 30, 2024)
Net sales	10,452,775	11,361,310
Cost of sales	3,082,010	3,383,217
Gross profit	7,370,764	7,978,092
Selling, general and administrative expenses	5,684,573	6,121,576
Operating profit	1,686,191	1,856,516
Non-operating income		
Interest and dividend income	13,591	25,932
Share of profit of entities accounted for using equity method	8,514	12,303
Rental income from real estate	41,337	42,008
Foreign exchange gains	2,865	-
Surrender value of insurance policies	5,305	725
Gain on sale of non-current assets	15,577	18,043
Other	12,043	5,413
Total non-operating income	99,236	104,425
Non-operating expenses		
Interest expenses	1,640	787
Foreign exchange losses	-	428
Depreciation of assets for rent	7,217	7,441
Provision of allowance for doubtful accounts	300	300
Loss on cancellation of insurance policies	4,758	-
Other	6,824	2,082
Total non-operating expenses	20,741	11,039
Ordinary profit	1,764,686	1,949,901
Extraordinary income		
Gain on sale of non-current assets	2,012	-
Gain on sale of investment securities	22,327	149,274
Gain on reversal of office transfer expenses	1,829	-
Total extraordinary income	26,168	149,274
Profit before income taxes	1,790,855	2,099,176
Income taxes-current	587,988	667,663
Income taxes-deferred	(25,201)	(19,664)
Total income taxes	562,787	647,998
Profit	1,228,068	1,451,177
Profit attributable to non-controlling interests	34,155	145,051
Profit attributable to owners of parent	1,193,912	1,306,125

**Semi-annual Consolidated Statement of Comprehensive Income**

(Thousands of yen)

	First six months of FY3/24 (Apr. 1, 2023 - Sep. 30, 2023)	First six months of FY3/25 (Apr. 1, 2024 - Sep. 30, 2024)
Profit	1,228,068	1,451,177
Other comprehensive income		
Valuation difference on available-for-sale securities	22,638	(101,544)
Foreign currency translation adjustment	134,495	118,870
Remeasurements of defined benefit plans, net of tax	406	1,117
Share of other comprehensive income of entities accounted for using equity method	729	1,009
Total other comprehensive income	158,270	19,452
Comprehensive income	1,386,338	1,470,630
Comprehensive income attributable to:		
Owners of parent	1,286,059	1,310,834
Non-controlling interests	100,279	159,796

**(3) Semi-annual Consolidated Statement of Cash Flows**

(Thousands of yen)

	First six months of FY3/24 (Apr. 1, 2023 - Sep. 30, 2023)	First six months of FY3/25 (Apr. 1, 2024 - Sep. 30, 2024)
Cash flows from operating activities		
Profit before income taxes	1,790,855	2,099,176
Depreciation	208,740	224,828
Amortization of goodwill	18,559	18,559
Increase (decrease) in allowance for doubtful accounts	(792)	723
Increase (decrease) in provision for bonuses	2,436	12,017
Increase (decrease) in provision for share-based payments	43,300	44,744
Increase (decrease) in retirement benefit liability	18,105	11,765
Increase (decrease) in provision for retirement benefits for directors (and other officers)	3,939	(30,141)
Interest and dividend income	(13,591)	(25,932)
Interest expenses	1,640	787
Share of loss (profit) of entities accounted for using equity method	(8,514)	(12,303)
Loss (gain) on sale of investment securities	(22,327)	(149,274)
Subsidy income	(1,049)	–
Decrease (increase) in trade receivables	(398,201)	(484,728)
Decrease (increase) in inventories	(60,461)	(12,704)
Increase (decrease) in trade payables	(22,973)	17,404
Increase (decrease) in advances received	198,362	193,691
Increase (decrease) in accrued consumption taxes	(63,182)	(74,023)
Other, net	276,968	15,032
Subtotal	1,971,814	1,849,623
Interest and dividends received	18,369	30,622
Subsidies received	1,049	–
Interest paid	(1,640)	(787)
Income taxes paid	(495,857)	(703,950)
Net cash provided by (used in) operating activities	1,493,735	1,175,508
Cash flows from investing activities		
Proceeds from withdrawal of time deposits	–	500,000
Proceeds from redemption of securities	–	1,000,000
Purchase of investment securities	(99,900)	(400,000)
Proceeds from sales of investment securities	72,327	203,024
Purchase of property, plant and equipment	(227,074)	(171,341)
Proceeds from sale of property, plant and equipment	16,243	18,045
Purchase of intangible assets	(4,876)	(34,513)
Proceeds from cancellation of insurance funds	63,482	–
Other, net	30,446	8,678
Net cash provided by (used in) investing activities	(149,350)	1,123,893

(Thousands of yen)

	First six months of FY3/24 (Apr. 1, 2023 - Sep. 30, 2023)	First six months of FY3/25 (Apr. 1, 2024 - Sep. 30, 2024)
Cash flows from financing activities		
Dividends paid	(970,623)	(687,204)
Other, net	(13,927)	(15,425)
Net cash provided by (used in) financing activities	(984,550)	(702,630)
Effect of exchange rate change on cash and cash equivalents	114,152	102,779
Net increase (decrease) in cash and cash equivalents	473,986	1,699,550
Cash and cash equivalents at beginning of period	12,795,930	13,959,093
Cash and cash equivalents at end of period	13,269,917	15,658,644

**(4) Notes to Semi-annual Consolidated Financial Statements****Assumption for Going Concern**

Not applicable.

**Significant Changes in Shareholders' Equity**

Not applicable.

**Segment and Other Information**

## 1. Overview of reportable segment

The Group's reportable segment is a component for which discrete financial information is available and which is regularly reviewed by the Group's highest decision-making body in order to determine management resources to be allocated to the segment and assess its performance.

There are two reportable operating segments: the water healthcare business and the medical business.

The water healthcare business includes EHW apparatus sales and associated operations. The medical business includes business operations in the fields of medical and preventive healthcare and regenerative medicine.

## 2. Information related to net sales and profit or loss of each reportable segment

## I. First six months of FY3/24 (Apr. 1, 2023 - Sep. 30, 2023)

(Thousands of yen)

	Reportable segment			Adjustments	Amounts recorded in semi-annual consolidated statement of income (Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	9,160,245	1,292,529	10,452,775	–	10,452,775
Inter-segment net sales and transfers	–	–	–	–	–
Total	9,160,245	1,292,529	10,452,775	–	10,452,775
Segment profit	1,491,902	194,288	1,686,191	–	1,686,191

Note: The segment profit subtotal is consistent with the operating profit of the semi-annual consolidated statement of income.

## II. First six months of FY3/25 (Apr. 1, 2024 - Sep. 30, 2024)

(Thousands of yen)

	Reportable segment			Adjustments	Amounts recorded in semi-annual consolidated statement of income (Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	9,943,038	1,418,271	11,361,310	–	11,361,310
Inter-segment net sales and transfers	–	–	–	–	–
Total	9,943,038	1,418,271	11,361,310	–	11,361,310
Segment profit	1,641,734	214,781	1,856,516	–	1,856,516

Note: The segment profit subtotal is consistent with the operating profit of the semi-annual consolidated statement of income.

*This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.*